Viking Therapeutics Q3 Earnings Call Highlights

Viking Therapeutics NASDAQ: VKTX reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of its lead candidate, VK2735.

MarketBeat • 19 hours ago

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving.

24/7 Wall Street • 11 hours ago

VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.

Zacks Investment Research • 10 hours ago

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.

Zacks Investment Research • 7 hours ago

Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock

Viking Therapeutics' maintenance data met upside criteria but failed to excite the market, with shares dropping post-release and dilution ongoing. VKTX is clearly pursuing a standalone strategy, ramping OpEx and infrastructure despite formidable competition from Eli Lilly and Novo Nordisk. Viking's multi-modal maintenance strategy—injectable induction followed by oral or monthly maintenance—addresses injection fatigue but faces a race against advancing competitors.

Seeking Alpha • 14 hours ago

Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)

Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for injectable VK2735, and SUNRISE trials for oral VK2735, are key 2025–2027 catalysts; >20% weight loss with strong safety could drive approval. Recent maintenance study data showed up to 21.7% mean weight loss and excellent tolerability with less frequent dosing, but competition and limited data durability remain concerns.

Seeking Alpha • 5 hours ago

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 29, 2026

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

--   VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion -- -- Strong Quarter-End Cash Position of $960 Million   -- Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, Oct. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its clinical pipeline and other corporate developments.

PRNewsWire • Oct 28, 2026

Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?

VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.

Zacks Investment Research • Oct 26, 2026

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.

24/7 Wall Street • Oct 25, 2026